Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 93, Issue -, Pages 721-729Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2017.07.002
Keywords
Coptisine; Atherosclerosis; Anti-inflammation; MAPK signaling pathways; NF-kappa B
Funding
- Chongqing Science and Technology Commission [cstc2015jcyjAoo61]
- Chongqing Educational Ministry [Kj1500637]
- Youth Doctoral Foundation of Chongqing Technology and Business University [1352013]
- Specialized Research Fund for the Doctoral Program of Higher Education of China [20130182110023]
Ask authors/readers for more resources
Coptisine is one of main bioactive compounds extracted from the traditional Chinese herbal medicine Rhizoma Coptidis. It is reported that coptisine can attenuate obesity-related inflammation and oxidant damage in Syrian golden hamsters. Therefore, coptisine may exhibit beneficial effects for the treatment of atherosclerosis (AS) due to its hypolipidemic and anti-inflammation activities. The present study investigated the anti-atherosclerotic and anti-inflammatory properties of coptisine using apoE-/- mice as AS model. The atherosclerotic plaque area of aorta, serum lipid profile and the expression of inflammatory cytokines were determined. After coptisine treatment, the serum level of TC, TG and LDL-C decreased; the serum level of IL-6, IL-1 beta and TNF-alpha were decreased; the mRNA levels of NF-kappa Bp65, VCAM-1, ICAM-1, IL-6 and IL-1 beta in both aorta and liver were down-regulated; the p-p38 and p-JNK1/2 protein expression level were decreased. Coptisine decreased atherosclerotic plaque area significantly through both anti-inflammation and lipid lowering effect. The anti-inflammatory effect of coptisine is achieved through inhibiting activation of MAPK signaling pathways and NF-kappa B nuclear translocation. Therefore, the combined anti-inflammation and lipid lowering effect of coptisine attributed the decreased atherosclerotic plaque area in coptisine treated apoE-/- mice. The results of this study will afford a novel application for coptisine in the treatment of atherosclerosis and other chronic inflammatory disease. (C) 2017 Published by Elsevier Masson SAS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available